Rapport complet - INESSS

Litton J, Rice A, Friedman N, Oden J, Lee MM, Freemark M. Insulin pump therapy in toddlers and preschoolchildren with type 1 diabetes mellitus. J Pediatr 2002;141(4):490-5.Manfrini S, Crino A, Fredrickson L, Pozzilli P. CSII versus intensive insulin therapy at onset of type 1diabetes: the Imdiab 8 Two-Year Randomised Trial. Diabetes 2002;51(Suppl 2):A4.Mathur R, Harmel AP. A comparison of continuous subcutaneous insulin infusion (CSII) therapy versusmultiple daily injection (MDI) therapy with premeal rapid acting insulin and glargine insulin inpatients with type 1 diabetes. Diabetes 2003;52(Suppl 1):A438.Mathur R, Sosa M, Somma L, Peters AL. Comparison of glycemic outcomes in patients with type 1 diabetes(T1dm) on continuous subcutaneous insulin infusion (CSII) or multiple daily injections (MDI)therapy. Diabetes 2002;51(Suppl 2):A107.McCarter RJ, Hempe JM, Gomez R, Chalew SA. Biological variation in HbA1c predicts risk of retinopathyand nephropathy in type 1 diabetes. Diabetes Care 2004;27(6):1259-64.Meyer L, Boullu-Sanchis S, Boeckler P, Sibenaler A, Treger M, Pinget M, Jeandidier N. Comparison ofglycemic control in 3 groups of type 1 diabetic patients treated with multiinjections and lispro(MDI), continuous subcutaneous insulin infusion with lispro (CSII) or continuous peritoneal insulininfusion (CPII): data of continuous subcutaneous glucose sensing (CGMS). Diabetes2002;51(Suppl 2):A124-5.Ministère de la Santé et des Services sociaux. Titres d'emploi, salaires et primes : échelles de salaire applicablesle 21 novembre 2002, le 1 er avril 2003 et le 21 novembre 2003. Québec, Qc : Conseil dutrésor, MSSS; 2003.Murphy NP, Keane SM, Ong KK, Ford-Adams M, Edge JA, Acerini CL, Dunger DB. Randomized crossovertrial of insulin glargine plus lispro or NPH insulin plus regular human insulin in adolescentswith type 1 diabetes on intensive insulin regimens. Diabetes Care 2003;26(3):799-804.Nathan DM, Lachin J, Cleary P, Orchard T, Brillon DJ, Backlund JY, et al. Intensive diabetes therapy andcarotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med 2003;348(23):2294-303.National Institute for Clinical Excellence (NICE). Guidance on the use of continuous subcutaneous insulininfusion for diabetes. Londres, Angleterre : NICE; 2003. Disponible : http://www. nice.org.uk/pdf/57_Insulin_pumps_fullguidance.pdf (consulté le 29 septembre 2004).National Institute for Clinical Excellence (NICE). Guidance on the use of long-acting insulin analogues forthe treatment of diabetes: insulin glargine. Londres, Angleterre : NICE; 2002.Nosadini R, Tonolo G. Relationship between blood glucose control, pathogenesis and progression of diabeticnephropathy. J Am Soc Nephrol 2004;15(Suppl 1):S1-5.Office of Medicaid Management. Insulin pump therapy for people with diabetes. DOH Medicaid Updatenovembre 2001, vol. 6, n o 11. Disponible : http://www.health.state.ny.us/nysdoh/mancare/omm/2001/nov2001.htm (consulté le 15 novembre 2004).Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos V, Lurati FM, et al. The CORE Diabetes Model:projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetesmellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med ResOpin 2004;20(Suppl 1):5-26.87